A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

Keyphrases

• Dapagliflozin 100%
• IgA Nephropathy (IgAN) 100%
• DAPA-CKD 100%
• Major Adverse Kidney Events 100%
• Placebo 54%
• Estimated Glomerular Filtration Rate 27%
• Albumin-to-creatinine Ratio 27%
• Chronic Kidney Disease 18%
• Kidney Failure 18%
• Composite Endpoint 9%
• Confidence Interval 9%
• Hazard Ratio 9%
• Adverse Events 9%
• Type 2 Diabetes Mellitus (T2DM) 9%
• Kidney Disease Progression 9%
• Disease-related 9%
• Kidney Disease 9%
• Serious Adverse Events 9%
• Safety Profile 9%
• Glomerulonephritis 9%
• Adverse Outcomes 9%
• Prolonged Survival 9%
• Drug Discontinuation 9%
• Estimated Glomerular Filtration Rate Decline 9%
• End-stage Kidney Disease 9%
• Renin-angiotensin-aldosterone System Blockers 9%

Medicine and Dentistry

• Dapagliflozin 100%
• Immunoglobulin A Nephropathy 100%
• Placebo 54%
• Glomerular Filtration Rate 36%
• Urinary System 27%
• Creatinine 27%
• Chronic Kidney Disease 27%
• Adverse Event 18%
• Renal Failure 18%
• Cardiovascular System 9%
• Biopsy 9%
• Maturity Onset Diabetes of the Young 9%
• Nephropathy 9%
• Hazard Ratio 9%
• Glomerulonephritis 9%
• End Stage Renal Disease 9%
• Renin Angiotensin Aldosterone System 9%
• Adverse Outcome 9%
• Disease Exacerbation 9%
• Immunosuppressant 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Dapagliflozin 100%
• Immunoglobulin A Nephropathy 100%
• Placebo 54%
• Creatinine 27%
• Chronic Kidney Failure 27%
• Adverse Event 18%
• Kidney Failure 18%
• Renin 9%
• Angiotensin 9%
• Non Insulin Dependent Diabetes Mellitus 9%
• Kidney Disease 9%
• End Stage Renal Disease 9%
• Disease Exacerbation 9%
• Adverse Outcome 9%
• Immunosuppressive Agent 9%
• Aldosterone 9%
• Glomerulonephritis 9%